NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)

CUSIP: N62509117

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / *W EXP 99/99/999
Total 13F shares
1,331,215
Share change
+34,544
Total reported value
$9,317,371
Price per share
$7.00
Number of holders
11
Value change
+$241,907
Number of buys
2
Number of sells
2

Quarterly Holders Quick Answers

What is CUSIP N62509117?
CUSIP N62509117 identifies NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q3 2024

As of 30 Sep 2024, NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by 11 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,331,215 shares. The largest 10 holders included Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Affinity Asset Advisors, LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Monashee Investment Management LLC, HRT FINANCIAL LP, Laurion Capital Management LP, Vestcor Inc, and TFC Financial Management, Inc.. This page lists 11 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.